Clinical Trial Update: Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on high-dose-rate monotherapy for low and intermediate risk prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• High-dose-rate monotherapy

Snippet

Sponsor: CSSS de Gatineau | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN